GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biogen Inc (BUE:BIIB) » Definitions » Other Net Income (Loss)

Biogen (BUE:BIIB) Other Net Income (Loss) : ARS-0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Biogen Other Net Income (Loss)?

Biogen's Other Net Income (Loss) for the three months ended in Mar. 2024 was ARS0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 was ARS-0 Mil.

Biogen's quarterly Other Net Income (Loss) increased from Sep. 2023 (ARS-0 Mil) to Dec. 2023 (ARS-0 Mil) and increased from Dec. 2023 (ARS-0 Mil) to Mar. 2024 (ARS0 Mil).

Biogen's annual Other Net Income (Loss) declined from Dec. 2021 (ARS3,525 Mil) to Dec. 2022 (ARS436 Mil) and declined from Dec. 2022 (ARS436 Mil) to Dec. 2023 (ARS0 Mil).


Biogen Other Net Income (Loss) Historical Data

The historical data trend for Biogen's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biogen Other Net Income (Loss) Chart

Biogen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Net Income (Loss)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4,746.02 431.31 3,524.55 435.89 -

Biogen Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Net Income (Loss) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biogen Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ARS-0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biogen Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Biogen's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.


Biogen (BUE:BIIB) Business Description

Address
225 Binney Street, Cambridge, MA, USA, 02142
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.

Biogen (BUE:BIIB) Headlines

From GuruFocus

Q3 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q1 2022 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2021 Biogen Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Biogen Inc Investor Day Transcript

By GuruFocus Research 01-22-2024